These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38860323)

  • 1. A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review.
    Efil SC; Bilgin B; Ceylan F; Karakaş H; Karahan İ; Özsan SN; Kosku H; Yaman Ş; Bülent Akıncı M; Dede DŞ; Yalçın B; Nahit Şendur MA
    J Oncol Pharm Pract; 2024 Oct; 30(7):1214-1239. PubMed ID: 38860323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review.
    Cui S; Wang N; Liang Y; Meng Y; Shu X; Kong F
    Int Immunopharmacol; 2024 Nov; 141():112903. PubMed ID: 39146783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials.
    Chen K; Wang X; Yue R; Chen W; Zhu D; Cui S; Zhang X; Jin Z; Xiao T
    Front Immunol; 2024; 15():1432813. PubMed ID: 39416776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
    Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR
    Ann Thorac Surg; 2024 Jul; 118(1):119-129. PubMed ID: 38316378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Top advances of the year: Perioperative therapy for lung cancer.
    Aredo JV; Wakelee HA
    Cancer; 2024 Sep; 130(17):2897-2903. PubMed ID: 38717993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of New Systemic Adjuvant Therapies for Non-small Cell Lung Cancer: Role of the Surgeon.
    Donington JS; Gitlitz B; Lim E; Opitz I; Kim YT; Altorki N
    Ann Thorac Surg; 2023 Jun; 115(6):1544-1555. PubMed ID: 36174774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
    Wu Y; Hu L; Zhang S; Zhang H
    Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
    Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative Nivolumab in Resectable Lung Cancer.
    Cascone T; Awad MM; Spicer JD; He J; Lu S; Sepesi B; Tanaka F; Taube JM; Cornelissen R; Havel L; Karaseva N; Kuzdzal J; Petruzelka LB; Wu L; Pujol JL; Ito H; Ciuleanu TE; de Oliveira Muniz Koch L; Janssens A; Alexandru A; Bohnet S; Moiseyenko FV; Gao Y; Watanabe Y; Coronado Erdmann C; Sathyanarayana P; Meadows-Shropshire S; Blum SI; Provencio Pulla M;
    N Engl J Med; 2024 May; 390(19):1756-1769. PubMed ID: 38749033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
    Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
    ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Spicer JD; Garassino MC; Wakelee H; Liberman M; Kato T; Tsuboi M; Lee SH; Chen KN; Dooms C; Majem M; Eigendorff E; Martinengo GL; Bylicki O; Rodríguez-Abreu D; Chaft JE; Novello S; Yang J; Arunachalam A; Keller SM; Samkari A; Gao S;
    Lancet; 2024 Sep; 404(10459):1240-1252. PubMed ID: 39288781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.
    Orillard E; Adhikari A; Malouf RS; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD015495. PubMed ID: 39136258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.